Research from Uppsala University, Department of Medical Sciences yields new data on chronic lymphocytic leukemia therapy

Data detailed in 'Rapamycin shows anticancer activity in primary chronic lymphocytic leukemia cells in vitro, as single agent and in drug combination' have been presented. According to a study from Uppsala, Sweden, "The mammalian target of rapamycin inhibitor rapamycin and its analogues show promising anticancer activity in various experimental tumor models and are presently evaluated in clinical trials. We, here, evaluated the in vitro activity of rapamycin with regard to tumor-type specificity and possible mechanisms of drug resistance in 97 tumor cell samples from patients and in a resistance-based cell line panel, using the fluorometric microculture cytotoxicity assay."

...

Want to see the full article?

• Purchase this article for only $3.00